Innovation1 Biotech Stock Probability of Future OTC Stock Price Finishing Over 0.001
| IVBT Stock | USD 0 0.00 0.00% |
Innovation1 |
Innovation1 Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innovation1 Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innovation1 Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Innovation1 Biotech generated a negative expected return over the last 90 days | |
| Innovation1 Biotech has some characteristics of a very speculative penny stock | |
| Innovation1 Biotech currently holds 554.4 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Innovation1 Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation1 Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation1 Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation1 Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation1 to invest in growth at high rates of return. When we think about Innovation1 Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (40.88 M) with loss before overhead, payroll, taxes, and interest of (17 K). | |
| Innovation1 Biotech currently holds about 636.16 K in cash with (3.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 75.0% of Innovation1 Biotech shares are held by company insiders |
Innovation1 Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innovation1 OTC Stock often depends not only on the future outlook of the current and potential Innovation1 Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innovation1 Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 20 M | |
| Short Long Term Debt | 10000.00 | |
| Shares Float | 2 M |
Innovation1 Biotech Technical Analysis
Innovation1 Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Innovation1 OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Innovation1 Biotech. In general, you should focus on analyzing Innovation1 OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Innovation1 Biotech Predictive Forecast Models
Innovation1 Biotech's time-series forecasting models is one of many Innovation1 Biotech's otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Innovation1 Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Innovation1 Biotech
Checking the ongoing alerts about Innovation1 Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Innovation1 Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Innovation1 Biotech generated a negative expected return over the last 90 days | |
| Innovation1 Biotech has some characteristics of a very speculative penny stock | |
| Innovation1 Biotech currently holds 554.4 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Innovation1 Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation1 Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation1 Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation1 Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation1 to invest in growth at high rates of return. When we think about Innovation1 Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (40.88 M) with loss before overhead, payroll, taxes, and interest of (17 K). | |
| Innovation1 Biotech currently holds about 636.16 K in cash with (3.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 75.0% of Innovation1 Biotech shares are held by company insiders |
Additional Tools for Innovation1 OTC Stock Analysis
When running Innovation1 Biotech's price analysis, check to measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.